Nasr Maha, Abdel-Hamid Sameh
a Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy , Ain Shams University , Cairo , Egypt.
Drug Dev Ind Pharm. 2016;42(4):636-43. doi: 10.3109/03639045.2015.1062512. Epub 2015 Jul 2.
CONTEXT: It is well known that microemulsions are mainly utilized for their transdermal rather than their dermal drug delivery potential due to their low viscosity, and the presence of penetration enhancing surfactants and co-surfactants. OBJECTIVE: Applying quality by design (QbD) principles, a tazarotene microemulsion formulation for local skin delivery was optimized by creating a control space. MATERIALS AND METHODS: Critical formulation factors (CFF) were oil, surfactant/co-surfactant (SAA/CoS), and water percentages. Critical quality attributes (CQA) were globular size, microemulsion viscosity, tazarotene skin deposition, permeation, and local accumulation efficiency index. RESULTS AND DISCUSSION: Increasing oil percentage increased globular size, while the opposite occurred regarding SAA/CoS, (p = 0.001). Microemulsion viscosity was reduced by increasing oil and water percentages (p < 0.05), due to the inherent high viscosity of the utilized SAA/CoS. Drug deposition in the skin was reduced by increasing SAA/CoS due to the increased hydrophilicity and viscosity of the system, but increased by increasing water due to hydration effect (p = 0.009). Models with very good fit were generated, predicting the effect of CFF on globular size, microemulsion viscosity, and drug deposition. A combination of 40% oil and 45% SAA/CoS showed the maximum drug deposition of 75.1%. Clinical skin irritation study showed that the aforementioned formula was safe for topical use. CONCLUSION: This article suggests that applying QbD tools such as experimental design is an efficient tool for drug product design.
背景:众所周知,微乳剂主要因其低粘度以及存在渗透促进表面活性剂和助表面活性剂,而被用于透皮给药而非真皮给药。 目的:应用质量源于设计(QbD)原则,通过创建一个控制空间来优化用于局部皮肤给药的他扎罗汀微乳剂配方。 材料与方法:关键配方因素(CFF)为油相、表面活性剂/助表面活性剂(SAA/CoS)和水的百分比。关键质量属性(CQA)为球状粒径、微乳剂粘度、他扎罗汀在皮肤中的沉积、渗透以及局部蓄积效率指数。 结果与讨论:增加油相百分比会增大球状粒径,而SAA/CoS则相反(p = 0.001)。由于所用SAA/CoS固有的高粘度,增加油相和水的百分比会降低微乳剂粘度(p < 0.05)。由于体系亲水性和粘度增加,增加SAA/CoS会减少药物在皮肤中的沉积,但由于水合作用增加水的含量则会使药物沉积增加(p = 0.009)。生成了拟合度非常好的模型,可预测CFF对球状粒径、微乳剂粘度和药物沉积的影响。40%油相和45% SAA/CoS的组合显示最大药物沉积率为75.1%。临床皮肤刺激性研究表明上述配方局部使用安全。 结论:本文表明应用诸如实验设计等QbD工具是药物产品设计的有效工具。
Drug Dev Ind Pharm. 2016
Pharm Dev Technol. 2016-12
Biomed Pharmacother. 2018-10-8
AAPS PharmSciTech. 2015-8-19
Pharm Dev Technol. 2016
Infect Disord Drug Targets. 2025
Pharmaceuticals (Basel). 2023-7-13
Pharmaceuticals (Basel). 2021-10-26
Res Pharm Sci. 2021-6-30